ProCE Banner Activity

Phase II Trial of Pimicotinib, a CSF-1R Inhibitor, for Previously Treated Chronic GVHD

Conference Coverage
Slideset

In this phase II trial, the CSF-1R inhibitor pimicotinib showed rapid and durable responses and favorable tolerability in heavily pretreated patients with chronic GVHD.

Released: December 10, 2024

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation